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Abstract
Background: Previous studies demonstrated breast cancer tumor tissue samples could be
classified into different subtypes based upon DNA microarray profiles. The most recent study
presented evidence for the existence of five different subtypes: normal breast-like, basal, luminal A,
luminal B, and ERBB2+.
Results: Based upon the analysis of 599 microarrays (five separate cDNA microarray datasets)
using a novel approach, we present evidence in support of the most consistently identifiable
subtypes of breast cancer tumor tissue microarrays being: ESR1+/ERBB2-, ESR1-/ERBB2-, and
ERBB2+ (collectively called the ESR1/ERBB2 subtypes). We validate all three subtypes statistically
and show the subtype to which a sample belongs is a significant predictor of overall survival and
distant-metastasis free probability.
Conclusion: As a consequence of the statistical validation procedure we have a set of centroids
which can be applied to any microarray (indexed by UniGene Cluster ID) to classify it to one of
the ESR1/ERBB2 subtypes. Moreover, the method used to define the ESR1/ERBB2 subtypes is not
specific to the disease. The method can be used to identify subtypes in any disease for which there
are at least two independent microarray datasets of disease samples.
Background
Perou et al. (2000) reported evidence for breast cancer
tumor subtypes defined by gene expression patterns.
From the results of hierarchical clustering of 65 breast can-
cer and normal breast samples based on their pattern of
expression of 496 intrinsic genes, Perou et al. (2000)
defined four groups: basal-like, Erb-B2 +, normal-breast-
like, and luminal epithelial/ER+. (The intrinsic genes were
those genes whose variation was significantly greater
between samples from different tumors than between
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The members of the basal-like group were characterized
by high expression of basal keratins 5/6 and 17. The onco-
protein ERBB2 was relatively overexpressed in the Erb-B2+
group members. The normal-breast-like samples resem-
bled normal breast tissue samples: basal epithelial cell
and adipose cell genes were relatively highly expressed
and luminal epithelial cell genes were expressed at rela-
tively low levels. Samples in the luminal epithelial/ER+
group came from patients who were estrogen receptor
(ER) positive and whose breast luminal cell markers were
relatively overexpressed [1].
As new data became available these breast cancer subtypes
were re-evaluated. Not only were the breast cancer sub-
type definitions modified, clinical outcomes were found
to be significantly different between the subtypes. Sørlie et
al. (2001) retained the basal-like, Erb-B2+ (re-named
ERBB2+ in Sørlie et al. (2001)), and normal-breast-like
groups but divided the luminal epithelial/ER+ group into
three subtypes: luminal A, luminal B, and luminal C. Cen-
troids corresponding to each of these six groups were
made on one dataset and used to classify the samples of
another dataset. All six groups were found in the second
dataset and differences in overall survival between the five
groups (ERBB2+ and luminal B were combined) were sig-
nificant [2].
Two years later, Sørlie et al. (2003) re-examined 84 of the
85 arrays used in the 2001 study and added 38 new breast
cancer tumor tissue arrays. Once again they found the
basal-like, normal breast-like, and ERBB2+ groups in their
hierarchical clustering dendrogram. The number of lumi-
nal groups, however, was reduced from three to two: lumi-
nal A and luminal B. Using centroids derived from the five
groups, they classified samples in two independent data-
sets to each of the groups. In one of the independent data
sets the time to distant metastasis curves significantly dif-
fered in the five groups [3]. (A similar analysis was not car-
ried out for the other dataset because follow-up data were
not available.)
The classification of the independent datasets was also
compared to the hierarchical clustering dendrograms of
these datasets. In some cases, the samples classified to the
same subtype grouped together in the dendrogram. This
observation led to the development of an array cluster val-
idation method described in Kapp and Tibshirani (2006).
In this paper, subtype centroids are used to classify sam-
ples independent of those used to define the subtypes.
The quality of the groups of samples classified to the same
subtype is measured by a quantity called the in-group pro-
portion. The in-group proportion is the proportion of sam-
ples in the group whose nearest-neighbor is also in the
same group. Thus, a high in-group proportion indicates a
group is cohesive (members of the group are close to each
other). The in-group proportion uses prediction error as a
measure of cluster quality. This is not a new idea, using
prediction error to gauge cluster quality has appeared in
several earlier studies: Dudoit and Fridlyand (2002),
Dudoit, Fridlyand, and Speed (2002), and Tibshirani and
Walther (2005).
To determine whether a group is significantly cohesive,
the in-group proportions are compared to null distribu-
tions generated by repeatedly permuting the centroids
within the box aligned with their principal components.
If an actual group's in-group proportion is higher than
100(1 - α) of the in-group proportions which comprise
the null distribution, then the corresponding subtype is
validated at the α significance level. Using this method
and the three datasets in Sørlie et al. (2003), the basal-like,
luminal B, and ERBB2+ subtypes were validated at an α =
0.05 significance level in at least one of the datasets. The
normal breast-like and luminal A subtypes, however, were
not validated at an α = 0.05 significance level [4]. The goal
of this study was not to modify and validate previously
defined subtypes. Instead, this study started from the
beginning, as Perou et al. (2000) did, just with more
microarray data. We also shared the same goal: to examine
as many breast cancer tumor microarrays as possible and
discover subtypes which may be biologically significant.
But our approach for identifying possible subtypes dif-
fered from previous studies. The previous studies hierar-
chically clustered the breast tissue samples' basal
expression of a group of genes selected based on charac-
teristics deemed a priori useful for classification. These
selection criteria, however, do not guarantee these genes
will be those which define subtypes. Since hierarchical
clustering is designed to be influenced by all the data,
genes which have no relationship with the subtypes but
which are included in the clustering could prevent the
dendrogram from partitioning the samples into the sub-
types.
Figure 1 presents two dendrograms to illustrate this phe-
nomenon. Ninety-eight samples were hierarchically clus-
tered (average linkage) twice. In Figure 1 (upper), they
were clustered using all available genes (23,946 genes); in
Figure 1 (lower), they were clustered on the 1,908 genes
that compose the ESR1/ERBB2 subtypes centroids. (How
these subtypes are defined and how the 1,908 genes were
found is described in later sections.) In both dendro-
grams, a sample's branch was colored according to which
ESR1/ERBB2 sample group it belonged. Branches of the
same color are much more cohesive in Figure 1 (lower)
than in Figure 1 (upper). Therefore, the choice of the
genes used to cluster the samples had a great impact upon
the hierarchical dendrogram.Page 2 of 15
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a collection of genes, some of which correlate highly and
some of which do not correlate highly. For samples which
belong to the same subtype, the expression levels of these
genes are similar; for samples which belong to different
subtypes, the expression levels of these genes differ. In
addition, the relationship between these genes' expression
levels for all the samples in the subtype is found consist-
ently (across datasets).
This concept of subtypes and the ideas illustrated in Figure
1 motivated our approach to identifying possible sub-
types. Instead of starting with a single hierarchical cluster-
ing of the samples on a large group of biologically relevant
genes, we hierarchically clustered the samples multiple
times on pairs of genes that passed the test described in
Step 2 (Procedure subsection of the Methods section) and
so we considered likely to define subtypes. Each hierarchi-
cal cluster yielded candidate sets of subtypes which we
attempted to validate. If the sample groups were validated
in the training dataset, validation datasets, and demon-
strated clinical differences, we examined the genes whose
expression significantly differed between the groups to see
if any genes correlated poorly with the genes that induced
the groups.
This approach is similar to that used in the previous
papers: the samples are hierarchically clustered to define
candidate subtypes and then validated. Our approach is
much more thorough, however. Many different sets of
candidate subtypes are considered and validation is done
statistically and by comparing the clinical outcomes.
Moreover, except for the statistical validation procedure,
all the other algorithms are standard and have been used
in published microarray papers. The statistical validation
procedure is new and the only option (to our knowledge)
for cluster validation using an independent dataset.
Hierarchical clusterings of training datasetFigure 1
Hierarchical clusterings of training dataset. Hierarchical clustering of all the training dataset samples (upper) on all 
23,9946 genes and (lower) on the 1,908 genes that define the three ERBB2/ESR1 subtype centroids. In both dendrograms, the 
training dataset samples are colored according to which ESR1/ERBB2 subtype they belong. ESR1+/ERBB2- samples are in red; 
ERBB2+ samples are in green; and ESR1-/ERBB2- samples are in blue.
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BMC Genomics 2006, 7:231 http://www.biomedcentral.com/1471-2164/7/231Using this approach, we find three subtypes of breast can-
cer tissues which were validated in the training and valida-
tion datasets. In other words, they are consistently found
in all datasets used in this study. We also show which of
the three subtypes a sample belonged to was a significant
predictor of overall survival (death irrespective of cause)
and distant metastasis-free probability (first recurrence
event was distant metastasis) in the validation dataset for
which we had clinical data. Furthermore, we demon-
strated that the subtypes were not solely based upon a
local pattern of gene expression. Not all the genes which
were significantly differentially expressed between the
subtypes correlated highly with the pair of genes initially
used to identify the subtypes.
Results and discussion
Results
Gene likely to specify subtypes
Once all the filters were applied, only 133 of the 23,946
genes in the training dataset were considered candidate
genes [see Additional file 1].
Statistical validation of possible subtypes
As described in the Procedure subsection (Methods sec-
tion), two genes that defined two sample groups which
had at least one gene significantly different between the
two sample groups were used to hierarchically cluster the
training dataset samples. Then each dendrogram was cut
to make a fixed number of sample groups (three or four).
The centroids associated with the groups were derived
using the nearest shrunken centroids method and used to
classify the training dataset samples. When the dendro-
grams were cut to make three groups, 129 pairs of genes
defined sample groups which all validated at the α = 0.05
significance level in the training dataset [see Additional
file 2]. In contrast, when the dendrogram was cut to make
four groups, only three pairs of genes defined sample
groups which all validated at the α = 0.05 significance
level in the training dataset (Table 1).
Of the 129 pairs of genes which resulted in three groups
that were all validated in the training dataset, two pairs'
candidate subtypes also were validated at the α 0.05 sig-
nificance level in all of the validation datasets. These pairs
are in bold in Additional file 2 and their p-values are in
Additional file 4 Tables 1, 2. These tables also show that if
an α = 0.01 significance level had been used, no gene pair
would have proceeded to Step 5 described in the Proce-
dure subsection of the Methods section. Of the pairs of
genes which resulted in four sample groups that were all
validated in the training dataset, no pair's groups were val-
idated at the α = 0.05 significance level in all of the vali-
dation datasets.
Biological validation of possible subtypes
The NKI dataset included clinical data on overall survival
and on distant metastasis-free probability (DMFP),
defined using distant metastasis as the first recurrence
event. Using this clinical data we determined whether or
not the thirteen sets of candidate subtypes which were val-
idated in all datasets had significant clinical differences.
First, the significance of the differences in the Kaplan-
Meier survival and DFMP curves were tested using the
Cox-Mantel log-rank test. Second, the likelihood ratio test
was used to determine whether or not the classifications
were significant factors in predicting overall survival or
DMFP in the presence of other common risk factors.
For both sets of groups, the log-rank test of the differences
between the survival and DMFP curves were significant at
the α = 0.05 level (Table 2). In addition, the groups
induced by BCMP11 (UniGene Cluster ID Hs.100686)
and ABCC11 (UniGene Cluster ID Hs.335891) were sig-
nificant predictors of overall survival and DMFP when
other known risk factors were included in the model at the
α = 0.05 and α = 0.10 levels, respectively. Moreover, the
groups induced by SLG39A6 (UniGene Cluster ID
Table 1: Pairs of genes resulting in four groups all validated in the 
training dataset at the α = 0.05 significance level.
First gene Second gene (s)
Hs.512643 GRB7
Hs.1657 LTF
ESR1 PDZK1IP1
The pairs of genes which induced four sample groups which all 
validated in the training dataset (α = 0.05) are listed. The first column 
lists the first gene in the pairs and the second column lists the second 
genes in the pairs. The UniGene Cluster ID is provided when the gene 
symbol is unavailable.
Table 2: Significance of overall survival and DFMP differences for groups validated in all datasets.
Gene pair Survival log-rank test p-value DMFP log-rank test p-value Survival likelihood ratio test 
p-value
DMFP likelihood ratio 
test p-value
BCMP11/ABCC11 6.7188 × 10-8 0.0005464543 0.005674599 0.06732856
SLC39A6/GATA3 4.836347 × 10-5 0.03727548 0.0516708 0.4392585
The results of the Cox-Mantel log-rank test and the likelihood ratio test for the four sets of groups which were statistically validated in all datasets 
are presented. The significance of the differences between the three groups in each set in overall survival and DMFP were tested. The p-values 
between 0.10-0.05 are in italics and p-values less than 0.05 are in bold.Page 4 of 15
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were significant predictors of overall survival (but not of
DMFP) at the α = 0.10 significance level (Table 2).
For the groups defined by BCMP11 and ABCC11, Groups
2 and 3 were associated with worse overall survival and
worse DMFP when compared to Group 1 (Table 3). Also,
belonging to Group 2 or Group 3 was a significant (α =
0.05) predictor for overall survival in the presence of other
known risk factors. Belonging to Group 2 was a significant
(α = 0.10) predictor for DMFP in the presence of other
known risk factors. Finally, the Kaplan-Meier curves in
Figure 2 show that Group 2 and Group 3 have similar
overall survival and metastasis-free probability over the
short-term. After 15 years, however, Group 3 has worse
overall survival and DMFP.
For the groups defined by SLC39A6 and GATA3, Group 2
and Groups 3 were associated with worse overall survival
and worse DMFP when compared to Group 1 (Table 4).
Only belonging to Group 3 was a significant (α = 0.05)
predictor of overall survival in the presence of other
Table 3: Multivariate analysis of mortality and DMFP risk factors and BCMP11/ABCC11.
Overall survival Distant metastasis-free probability
Hazard ratio (95% confidence 
interval)
p-value Hazard ratio (95% confidence 
interval)
p-value
BCMP11/ABCC11: Group 2 vs. Group 1 2.124 (1.0923 – 4.130) 0.0260 1.759 (0.948 – 3.263) 0.073
BCMP11/ABCC11: Group 3 vs. Group 1 2.155 (1.1874 – 3.913) 0.0120 1.452 (0.817 – 2.580) 0.200
Age (decade) 0.688 (0.4792 – 0.988) 0.0430 0.736 (0.523 – 1.035) 0.078
Tumor diameter (cm) 1.022 (0.9967 – 1.048) 0.0890 1.034 (1.010 – 1.058) 0.006
Lymph node status (positive node) 1.010 (0.8309 – 1.228) 0.9200 1.045 (0.886 – 1.234) 0.600
Tumor grade: Poorly diff. vs. Intermediate 1.185 (0.6586 – 2.131) 0.5700 0.979 (0.560 – 1.713) 0.940
Tumor grade: Well diff. vs. Intermediate 0.240 (0.0828 – 0.698) 0.0088 0.403 (0.190 – 0.855) 0.018
Vascular invasion: 1–3 vessels vs. ≥ 4 vessels 0.627 (0.2150 – 1.829) 0.3900 0.530 (0.198 – 1.424) 0.210
Vascular invasion: 0 vessels vs. ≥ 4 vessels 0.589 (0.1322 – 2.621) 0.4900 0.560 (0.145 – 2.158) 0.400
Mastectomy vs. breast conserving therapy 1.119 (0.6933 – 1.807) 0.6400 1.193 (0.750 – 1.895) 0.460
Chemo and hormonal therapy v. no adjuvant therapy 0.724 (0.3281 – 0.1596) 0.4200 0.502 (0.246 – 1.022) 0.057
Results of the multivariate analysis of mortality risk factors (left) and DMFP risk factors (right). The group classifications determined by the BCMP11 
and ABCC11 gene pair are included. The p-values less than 0.05 are in bold. The p-values significant at an α = 0.10 level but not at an α = 0.05 
significance level are in italics.
Kaplan-Meier curves for overall survival and DMFP for the three groups defined by BCMP11/ABCC11Figure 2
Kaplan-Meier curves for overall survival and DMFP for the three groups defined by BCMP11/ABCC11. The Kap-
lan-Meier survival curves (left) and DMFP curves (right) for each of the three groups defined by BCMP11 and ABCC11.
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BMC Genomics 2006, 7:231 http://www.biomedcentral.com/1471-2164/7/231known risk factors. The Kaplan-Meier curves in Figure 3
show that Group 3 consistently had the worse overall sur-
vival and DMFP. Group 2 initially resembled Group 3 in
terms of overall survival and DMFP, but after time, Group
2 looks more like Group 1.
Notice that estrogen receptor status was not included in
the multivariate analysis. Estrogen receptor status was not
included because the expression of ESR1 has been shown
to be positively correlated with the expression of BCMP11
and GATA3 [5,6]. Estrogen receptor status, expression of
BCMP11, and expression of GATA3 are confounding vari-
ables. Therefore, including both estrogen receptor status
and the subtypes defined by BCMP11/ABCC11 or
SLC39A6/GATA3 may produce inaccurate results.
Discussion
BCMP11/ABCC11 and SLC39A6/GATA3 groups as 
subtypes
Both sets of three groups defined by the BCMP11/ABCC11
gene pair and the SLCS9A6/GATAS gene pair have many
of the characteristics of subtypes (see Background sec-
Table 4: Multivariate analysis of mortality and DMFP risk factors and SLC39A6/GATA3.
Overall survival Distant metastasis-free probability
Hazard ratio (95% confidence 
interval)
p-value Hazard ratio (95% confidence 
interval)
p-value
SLC39A6/GATA3: Group 2 vs. Group 1 1.557 (0.7914 – 3.061) 0.2000 1.208 (0.621 – 2.347) 0.5800
SLC39A6/GATA3: Group 3 vs. Group 1 1.675 (0.9739 – 2.882) 0.0620 1.207 (0.715 – 2.038) 0.4800
Age (decade) 0.678 (0.4722 – 0.973) 0.0350 0.720 (0.513 – 1.011) 0.0580
Tumor diameter (cm) 1.022 (0.9964 – 1.048) 0.0940 1.033 (1.009 – 1.058) 0.0067
Lymph node status (positive node) 1.019 (0.8396 – 1.237) 0.8500 1.054 (0.894 – 1.241) 0.5300
Tumor grade: Poorly diff. vs. Intermediate 1.403 (0.7994 – 2.463) 0.2400 1.117 (0.657 – 1.901) 0.6800
Tumor grade: Well diff. vs. Intermediate 0.222 (0.0769 – 0.643) 0.0055 0.381 (0.180 – 0.806) 0.0120
Vascular invasion: 1–3 vessels vs. ≥ 4 vessels 0.678 (0.2352 – 1.956) 0.4700 0.577 (0.217 – 1.532) 0.2700
Vascular invasion: 0 vessels vs. ≥ 4 vessels 0.638 (0.1456 – 2.794) 0.5500 0.597 (0.157 – 2.263) 0.4500
Mastectomy vs. breast conserving therapy 1.078 (0.6682 – 1.738) 0.7600 1.165 (0.733 – 1.851) 0.5200
Chemo and hormonal therapy v. no adjuvant therapy 0.718 (0.3291 – 1.567) 0.4100 0.496 (0.245 – 1.005) 0.0510
Results of the multivariate analysis of mortality risk factors (left) and DMFP risk factors (right). The group classifications determined by the SLC39A6 
and GATA3 (Hs.524134) gene pair are included. The p-values less than 0.05 are in bold. The p-values significant at an α = 0.10 level but not at an α 
= 0.05 significance level are in italics.
Kaplan-Meier curves for overall survival and DMFP for the three groups defined by SLC39A6/GATA3Figure 3
Kaplan-Meier curves for overall survival and DMFP for the three groups defined by SLC39A6/GATA3. The Kap-
lan-Meier survival curves (left) and DMFP curves (right) for each of the three groups defined by SLC39A6 and GATA3.
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BMC Genomics 2006, 7:231 http://www.biomedcentral.com/1471-2164/7/231tion). First, they were reproducible: in both cases, the
three groups were found in all the datasets at the α = 0.05
level [see Additional file 4 Tables 1, 2]. Second, both sets
of three groups were significantly different clinically (this
applies to a greater extent to the BCMP11/ABCC11 groups
than to the SLC39A6/GATAS). Based upon the log-rank
test the survival differences and DMFP differences
between the three BCMP11/ABCC11 groups and between
the three SLC39A6/GATAS groups were significant at the α
= 0.05 level (Table 2 and Figures 2, 3). Furthermore, at the
α = 0.10 level, the BCMP11/ABCC11 groups were signifi-
cant predictors of overall survival and distant metastasis
as first recurrence event. At the same level of significance,
the SLC39A6/GATAS groups were significant predictors of
overall survival, but not of distant metastasis as first recur-
rence event (Tables 3, 4).
Figure 4 demonstrates that both sets of three groups also
possess the final desirable characteristic of subtypes as
defined in the Background section: Genes which do not
correlate highly with the genes used to define the centro-
ids are significantly differentially expressed between the
groups. For the BCMP11/ABCC11 groups 1,121 genes
were significantly differentially expressed between the
three groups (determined by SAM, ∆ = 0.49315 and the
90th percentile of false positives = 0). The absolute Pear-
son's (centered) correlation was computed between each
gene and BCMP11, and between each gene and ABCC11.
Figure 4 (left) is the histogram of the maximum of those
two values for all 1,121 genes. Similarly, for the SLC39A6/
GATAS groups 1,103 genes were significantly differen-
tially expressed between the three groups (∆ = 0.47040
and the 90th percentile of false positives = 0). Figure 4
(right) is the histogram of the maximum of the correla-
tions between SLC39A6 and each of the 1,103 genes and
between GATAS and each of the 1,103 genes.
In both histograms, some of the area of the histogram is
below 0.5. Therefore, for both sets of three groups, genes
which significantly differed between the three groups
were not always highly (positively or negatively) corre-
lated with the genes which defined the groups.
Similarity of BCMP11/ABCC11 and SLC39A6/GATA3 
groups
Of the 1,121 genes which significantly differed between
the BCMP11/ABCC11 groups, 78.06% were also signifi-
cantly differentially expressed between the SLC39A6/
GATAS groups. Eight-hundred and seventy-five genes
were significantly differentially expressed between the two
sets of groups. In fact, all 204 genes used to define the
SLC39A6/GATA3 centroids were included in the 1,908
genes used to define the BCMP11/ABCC11 centroids. Fur-
thermore, when the classifications of the training dataset
were compared, all of the members of SLC39A6/GATA3
Group 1 were in BCMP11/ABCC11 Group 1, all of the
Histograms of correlations between significantly differentially expressed genes and the genes that induced themFigure 4
Histograms of correlations between significantly differentially expressed genes and the genes that induced 
them. (Left) Histogram of the maximum absolute Pearson's (centered) correlation of the genes that are significantly differen-
tially expressed between the BCMP11/ABCC11 groups with BCMP11 and with ABCC11. (Right) Histogram of the maximum 
absolute Pearson's (centered) correlation of the genes that are significantly differentially expressed between the GATA3/
SLC39A6 groups with GATA3 and with SLC39A6.
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BMC Genomics 2006, 7:231 http://www.biomedcentral.com/1471-2164/7/231members of SLC39A6/GATA3 Group 3 were in BCMP11/
ABCC11 Group 3, and the majority of the members of
SLC39A6/GATA3 Group 2 were in the BCMP11/ABCC11
Group 2 (Table 5 upper).
Therefore, the groups defined by the two sets of centroids
are very similar. Since the BCMP11/ABCC11 groups were
more significantly different clinically, we will restrict our
attention to them.
For each BCMP11/ABCC11 subtype, the genes most signif-
icantly differentially expressed between it and the other
two BCMP11/ABCC11 were found using SAM and the
training dataset. In Figure 5, the most significantly differ-
entially expressed genes present in all datasets and used to
define the BCMP11/ABCC11 centroids for each SAM anal-
ysis are shown.
Notice that the expression of the estrogen receptor 1
(ESR1) distinguishes Group 1 from Groups 2 and 3. ESR1
is overexpressed in Group 1 and underexpressed in
Groups 2 and 3. Moreover, ERBB2 is overexpressed in
Group 2, but underexpressed in Groups 1 and 3. As a con-
sequence, from this point on, BCMP11/ABCC11 Group 1
will be referred to as the ESR1+/ERBB2- subtype; BCMP11/
ABCC11 Group 2 will be referred to as the ERBB2+ sub-
type; and BCMP11/ABCC11 Group 3 will be referred to as
the ESR1-/ERBB2- subtype. Collectively, they will now be
referred to as the ESR1/ERBB2 subtypes.
Comparison of ESR1/ERBB2 subtypes and Sørlie et al. 
(2003) subtypes
One of the ESR1/ERBB2 subtypes' names is the same as
one of the Sørlie et al. (2003) subtypes: ERBB2+. Although
none of the ESR1/ERBB2 subtypes exactly matched any of
the Sørlie et al. (2003) subtypes, the vast majority of the
samples in four of the Sørlie et al. (2003) subtypes fell in
one ESR1/ERBB2 subtype (Table 5 lower). First, all of the
normal-like samples, all of the luminal A samples, and 9
of the eleven luminal B samples were classified to the
ESR1+/ERBB2- subtype. Second, 7 of the 11 samples clas-
sified to the Sørlie et al. (2003) ERBB2+ subtype were also
classified to the ESR1/ERBB2 ERBB2+ subtype. Finally, the
samples classified to the basal subtype were fairly evenly
distributed among the three ESR1/ERBB2 subtypes.
Existence of other subtypes
Even though we only have shown evidence for the exist-
ence of three subtypes, that does not preclude the exist-
ence of other subtypes. For example, using fluorescent in
situ hybridization (FISH) and histological staining, some
breast cancer tumors belong to ERBB2 amplified and ER+
group [7]. Therefore, one may have expected this study to
have found an ESR1+/ERBB2+ subtype. In our training and
testing datasets, the few patients who we knew were
ERBB2 amplified based upon FISH did not have especially
high ESR1 expression levels. So the most likely explana-
tion for not finding an ERBB2+/ESR1+ subtype is that
ERBB2 and ER amplified samples did not form a group
distinct from the ERBB2 amplified but ER unamplified
samples. Nevertheless, three of the four samples known to
be ESR1+/ERBB2+ by FISH were classified to the ERBB2+
group. The fourth sample was classified to the ESR1+/
ERBB2- group.
Conclusion
To summarize, we started from the very beginning with-
out consideration for the results described in Perou et al.
(2000), Sørlie et al. (2001), or Sørlie et al. (2003). With
microarray data from hundreds of breast tissue samples
(normal and tumor), we compiled a collection of 133
candidate genes based upon percentage of data present,
variation, and ability to create two groups of samples sig-
nificantly differing in a large number of genes. Using that
collection of candidate genes, pairs of genes which gener-
ated three or four candidate sample subtypes that were
found in the training and validation datasets were identi-
fied. Of these two sets of three groups, only one set had
candidate subtypes which were significant predictors (α =
0.10) of overall survival and DMFP (when other known
risk factors, not including estrogen receptor status, were
controlled for): the ESR1/ERBB2 subtypes. Thus we have
identified three breast cancer tumor subtypes that are con-
sistently identified in all the datasets we examined and
have biological relevance.
Table 5: Comparison with BCMP11/ABCC11 subtypes.
BCMP11/ABCC11
Group 1 Group 2 Group 3
SLC39A6/GATA3 Group 1 42 0 6
Group 2 8 21 3
Group 3 0 0 16
Sørlie subtype Normal-like 6 0 0
ERBB2+ 4 7 0
Luminal A 28 0 0
Luminal B 9 2 0
Basal 5 8 6
(Upper) Each of the training dataset samples was classified twice: first 
to one of the SLC39A6/GATA3 groups and then to one of the BCMP11/
ABCC11 subtypes. The entries in the table are the number of samples 
classified to the SLC39A6/GATA3 (row) subtype and to the BCMP11/
ABCC11 subtype (column). (Lower) A subset of the Norway/Stanford 
samples were classified to one of the three subtypes presented in this 
paper and the classification is compared with the Sørlie et al. (2003) 
classification. Each entry in the table is the number of Norway/
Stanford samples classified to the Sørlie et al. (2003) subtype (row) 
and the BCMP11/ABCC11 subtype (column)Page 8 of 15
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BMC Genomics 2006, 7:231 http://www.biomedcentral.com/1471-2164/7/231This paper is intended to be a starting point for further
research. The ESR1/ERBB2 centroids can be applied to any
microarray sample indexed by UniGene Cluster ID to clas-
sify it to one of the three subtypes. Thus, these centroids
represent a standard way of determining the subtype of a
breast cancer tumor tissue sample. As a consequence, fur-
ther research is needed to determine whether or not sub-
populations of these subtypes exist. If they do, clinical and
biological characterization of them will be required.
Although this paper focused on breast cancer, it also pro-
vides an answer to this question: How does one identify
subtypes? Just as our subtypes differ from those in previ-
ous papers, our answer to this question also differs.
Instead of using of all of the genes likely to define sub-
types to hierarchically cluster the training dataset samples,
we only used pairs of genes in our hierarchical clusterings
to prevent genes that are independent of a sample parti-
tion from obscuring it (see Figure 1). This approach
proved to be fruitful and produced two similar sets of
groups which were found in all our datasets and were sig-
nificant predictors of overall survival or DMFP. Therefore,
the methods presented here are useful for identifying sub-
types of any disease provided that at least two independ-
ent microarray datasets of diseased samples are available.
Methods
Materials
Five microarray datasets were used in this study (three of
which have appeared in previously published papers):
NKI dataset [8,9], Sørlie dataset [3], Zhao/Langerød data-
set [10], Korean dataset and Norway/Stanford dataset.
[See Additional file 3 for detailed lists of the arrays in each
dataset.] The Sørlie and Zhao/Langerød datasets are pub-
licly available from the Stanford Microarray Database
(SMD) [11]. When data were downloaded from SMD, the
control spots were included but the flagged spots were
not. All of the arrays associated with Zhao et al. (2004)
were used, but only the arrays not used for selection of the
intrinsic genes (disease_state_design) from the Sørlie et al.
(2003) paper were used.
The NKI dataset and associated clinical data are also pub-
licly available [12]. Before this file was used, however, the
Training dataset samples dendrogram clustered on BCMP11/ABCC11 centroid genesFigure 5
Training dataset samples dendrogram clustered on BCMP11/ABCC11 centroid genes. Thirty centroid genes 
present in all datasets that best distinguish the three BCMP11/ABCC11 groups. The first group of genes are the top ten genes 
that distinguish Group 1 from Groups 2 and 3; the second group of genes are the top ten genes that distinguish Group 2 from 
Groups 1 and 3; and the last group of genes are the top ten genes that distinguish Group 3 from Groups 1 and 2. The samples 
in BCMP11/ABCC11 Group 1 (ERBB2-/ESR1+) are in red; the samples in BCMP11/ABCC11 Group 2 (ERBB2+) are in green; and 
the samples in the BCMP11/ABCC11 Group 3 (ESR1-/ERBB2-) are in blue.Page 9 of 15
(page number not for citation purposes)
BMC Genomics 2006, 7:231 http://www.biomedcentral.com/1471-2164/7/231UniGene Cluster IDs were updated (Build 180 released
January 20, 2005) and the logarithm base was changed
from ten to two to make it compatible with the other data-
sets.
The Norway/Stanford dataset was composed of samples
from 60 tumors, 45 of which came from Ullevål Univer-
sity Hospital (Norway) and 15 of which came from Aker-
shus University Hospital (Norway). DNA microarray
analysis was carried out at Stanford University Medical
Center (United States of America), however. The 81 arrays
in the Korean dataset were from patients at Seoul National
University College of Medicine.
For the Norway/Stanford, Korean, Zhao, and NKI data-
sets, but not the Sørlie dataset, the RNA was amplified
prior to hybridization to the cDNA microarrays [13,14].
The validation method used in this paper required a train-
ing dataset and at least one independent testing dataset.
The Norway/Stanford, Korean, and Zhao/Langerød data-
sets were all made on the same microarray platform using
the same RNA preparation protocol and were indexed by
clone ID (not UniGene cluster ID), so they could be easily
combined and used as training and testing datasets.
Tumor samples were taken from three different popula-
tions and the distributions of the samples' clinical charac-
teristics in the Norway/Stanford, Korean, and Zhao/
Langerød datasets are not equal, however, so we followed
the procedure described below and divided each of the
three datasets and subsequently pooled groups to make
the training dataset and the testing dataset. If we had used
the Norway/Stanford and Korean datasets as the training
dataset and the Zhao/Langerød dataset as the test set (or
Training and testing datasets formationFigure 6
Training and testing datasets formation. This diagram shows how the training dataset and testing dataset were formed. 
For the top row, the numbers in the boxes represent the number of samples that were combined to form the training dataset 
and testing dataset. The arrows point to the dataset in which they were put.
Norway/Stanford dataset Korean dataset Zhao/Langerod dataset
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(page number not for citation purposes)
BMC Genomics 2006, 7:231 http://www.biomedcentral.com/1471-2164/7/231some similar combination), we risked finding subtypes
that were specific to a group of subjects.
More specifically, each of the Norway/Stanford, Korean,
and Zhao/Langerød datasets was randomly divided into a
training set and testing set of approximately equal sizes.
Next, the three training sets were combined and the three
testing sets were combined. The arrays from normal
patients and redundant arrays (arrays which appeared in
more than one dataset) were subsequently removed leav-
ing 90 arrays in the training dataset and 96 arrays in the
testing dataset. The Sørlie and NKI datasets were used for
validation. The testing dataset, Sørlie dataset, and NKI
dataset taken together are referred to as the validation data-
sets (Figure 6).
The random splits of the Norway/Stanford, Korean, and
Zhao/Langerød datasets were done once. As long as the
composition of the training and testing datasets are simi-
lar, the results should not depend upon these random
splits. More specifically, if one subtype is absent from the
training or testing dataset, the results will be affected. As
will be shown in the Statistical analysis subsection below,
the three breast cancer subtypes we identified are found in
the training dataset and all the validation datasets.
Furthermore, an examination of Additional file 4 Figure 1
shows that the proportions of samples in each of the three
subtypes are high enough to make it unlikely that all the
samples of one or more subtypes will be absent from the
training dataset or testing dataset after a random split.
Finally, before they were used, the training, testing, and
Sørlie datasets' annotation was changed from clone ID to
UniGene Cluster ID. In each of the three datasets, if a
clone corresponded to more than one UniGene Cluster
ID, then the clone's entries were replicated. The entries for
clones which corresponded to the same UniGene Cluster
ID were then averaged together over the clones. The corre-
spondence between UniGene Cluster ID and clone ID was
dictated by UniGene_Curated_110504, a curated synthetic
gene list provided by SMD. This gene list does not include
defective clones (e.g. incorrectly labeled clones).
Statistical analysis
The public domain statistical program R version 2.2.0
[15,16] was used for all analysis. In addition to many
functions in the base R package, the Significance Analysis
of Microarrays (SAM) [17] function in the R package
siggenes and the Prediction Analysis for Microarrays
(PAM) R package pamr were used to form centroids and
analyze the sample groups. PAM implements the nearest
shrunken centroids method described in Tibshirani et al.
(2002).
Statistical validation was done according to the procedure
described in Kapp and Tibshirani (2006) (an implemen-
tation of the algorithm is in the R package clusterRepro)
while biological validation was done using the coxph (fits
Cox proportional hazards models) and survdiff (applies
the Cox-Mantel log-rank test) functions in the R survival
package.
Procedure
The procedure we followed was more complicated than
that of the previous papers. The additional complexity
was a reasonable price to pay for a more comprehensive
search for the subtypes of breast cancer, however. Instead
of a priori choosing a single set of subtype-defining genes
(e.g. an intrinsic gene list), as was done in the earlier
papers, we defined a subset of genes we considered likely
to define subtypes based on the test described in Step 2
and used them to generate 17,556 (= 2 × ) sets of
possible subtypes. Then we examined every set seeking the
ones that could be biologically and statistically validated.
Our procedure is described in detail below.
Step 1. Filter genes
Initially each of the training dataset genes (indexed by
UniGene Cluster ID) was considered for determining sub-
types. Genes which had a standard deviation less than 1.5
and had less than 90% of data present in the training data
were removed. The percentage of genes which had a stand-
ard deviation less than 1.5 was 98.6%. Of those 327
genes, 169 had at least 90% data present (196 genes had
at least 85% genes present and 229 genes had at least 80%
data present). Therefore, the number of genes was reduced
from 23,946 to 169 (Figure 7).
After this step, the missing data in all four datasets were
imputed with the gene average. In each dataset, the miss-
ing values for a given gene were replaced by the average of
the present expression values for that gene. From this
point on, none of the datasets contains any missing val-
ues.
Step 2. Identify genes likely to specify subtypes
Each of the 169 seed genes which passed through the fil-
ters was used individually to hierarchically cluster (Eucli-
dean distance, average linkage) the training dataset
samples (R function hclust). The R function cutree auto-
matically cut each dendrogram (from the top down) to
form two groups of samples. The two-sample unpaired T-
statistic was used to determine the number of genes whose
expression levels differed significantly between the two
groups. (These T-statistics were not related to the in-group
proportion or the validation of subtypes.) For a given
133
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BMC Genomics 2006, 7:231 http://www.biomedcentral.com/1471-2164/7/231sample grouping and each gene j (1 ≤ j ≤ 23,946), the fol-
lowing statistic was computed:
where
The Xi,j were the expression levels for gene j for the sam-
ples in the first group defined by the dendrogram and the
Yi,j were the expression levels for the same gene for the
samples in the second group defined by the dendrogram.
There were nj data for gene j in the first group and mj data
for gene j in the second group. The genes which defined
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Steps of the procedureFigure 7
Steps of the procedure. Pictorial representation of steps 1 – 5 described in the Procedure subsection of the Methods sec-
tion. (Upper) Filter all 23,946 genes by removing genes with at least 10% missing data or a standard deviation less than 1.5. 
Keep all seed genes that define two training dataset sample groups between which at least one of the 23,946 genes is signifi-
cantly differentially expressed. Repeatedly do the following steps. Select two of the 133 candidate genes and hierarchically clus-
ter the training dataset sample on these two genes. Cut the dendrogram from the top down to produce three groups of 
samples. Cut the same dendrogram from the top down again to produce four groups of samples. Use PAM to determine which 
of the 23,946 genes best define centroids for the training dataset sample groups obtained from the dendrogram. Form the cen-
troids by taking only the data for those genes and averaging over the sample classified to the same group. Use the centroids to 
classify the training dataset samples. (Lower) If all the groups are validated in the training dataset then use the centroids to clas-
sify the testing datasets' samples. If all the groups are validated in all of the validation datasets, then the significance of the 
groups' clinical difference is determined (not pictured).
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BMC Genomics 2006, 7:231 http://www.biomedcentral.com/1471-2164/7/231groups with at least one Tj significant at the α = 0.05 level
were considered genes likely to define subtypes (called
candidate genes). Seed genes that induced two sample
groups between which a lot of genes were significantly dif-
ferentially expressed were not treated any differently than
seed genes that induced two sample groups between
which one gene was significantly differentially expressed:
both became candidate genes. Of the 169 seed genes, 133
were candidate genes: genes that defined two groups
between which at least one gene was significantly differen-
tially expressed. (See Figure 7.)
This is a very simple way to look for differentially
expressed genes. A more sophisticated approach is
described in McLachlan et al. (2002). They identify differ-
entially expressed genes by fitting a mixture of two densi-
ties (Gaussian or Student's t). The likelihood ratio test is
used to determine whether or not two densities fit better
than a single density. If that is so, a gene is considered to
be differentially expressed. This method for filtering genes
is implemented in the first step of the EMMIX-GENE algo-
rithm [18]. An even more sophisticated approach to the
identification of differentially expressed genes can be
found in McLachlan et al. (2006). When we used the
former procedure to filter genes, none of the 169 seed
genes were considered to be significantly differentially
expressed (results not shown).
Step 3. Combine genes pairwise to identify possible subtypes
Each of the 133 candidate genes was combined with every
other candidate gene to generate candidate sets of sub-
types. Each pair of candidate genes was used to hierarchi-
cally cluster (Euclidean distance, average linkage) the
training data samples. A pair of genes, instead of more,
was used because it was the most simple choice and least
likely to miss obvious, broad groupings of samples. If real
subtypes were defined by two genes, the inclusion of one
or more additional genes may have prevented the hierar-
chical dendrogram from identifying the real subtypes. Sin-
gle genes were not used because that would essentially
replicate the previous step.
All of the 8,778 (= ) dendrograms were cut twice:
first to define three groups and then to define four groups.
A gene that is differentially expressed between groups of
samples will be differentially expressed between at least
two sample groups. Therefore, when two such genes are
combined to partition the samples, at the very least they
will partition the samples into two groups (e.g., the genes
are highly correlated), three groups (e.g., one gene subdi-
vides one of the two sample groups induced by the other
gene), or four groups (e.g., both genes divide the samples
into two independent sets of two groups). When a pair of
genes defines two sample groups they are most likely very
similar to at least one set of the two sample groups
defined by the individual genes. We have already chosen
the candidate genes to divide the samples into two poten-
tially interesting groups. The next logical step is to look for
additional complexity in the interaction between pairs of
genes. Therefore, the hierarchical dendrogram was cut to
make three groups and four groups.
For each of the two cuts, the nearest shrunken centroids
method identified the fewest number of genes (out of
23,946 genes) needed to form centroids minimizing the
cross-validation misclassification error. Since the nearest
shrunken centroids method used cross-validation, if any
of the three (or four) groups had fewer than five samples,
centroids corresponding to the classification were not
made and no attempt to validate the groups was made. In
addition, if there were fewer than three genes in the cen-
troids, validation of the associated groups was not
attempted because the Pearson's (centered) correlation
coefficient between samples could not be computed with-
out at least three genes. Once the nearest shrunken centro-
ids method identified the genes, a set of (three or four)
centroids was made by averaging these genes' expression
levels over the samples classified to the same candidate
subtype. (See Figure 7.)
As in Step 2, alternative methods for executing Step 3
exist. In the EMMIX-GENE procedure of McLachlan et al.
(2006), for example, a large collection of genes is reduced
to a smaller representative set. All of the genes are clus-
tered and a few representative members of the groups
stand in for the entire group. If this method was used, the
computation could be greatly reduced and a larger gene
list could have been considered. Using this method, how-
ever, requires one to select the representative member of
each group. The correct way to do that is not obvious.
Step 4. Attempt to statistically validate the possible subtypes
Each candidate set of centroids formed in the previous
step was applied to classify the training dataset in an
attempt to validate the corresponding possible subtypes.
If all of the possible subtypes were validated at the α =
0.05 significance level, then the possible subtypes were
pursued in all the validation datasets. (See Figure 7.)
Step 5. Analyze the clinical differences between the possible subtypes
Each candidate set of centroids corresponding to possible
subtypes validated in the training dataset and all the vali-
dation datasets were used to classify the NKI samples
133
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ble for this dataset.
The likelihood ratio and the Cox-Mantel log-rank tests
were used to determine whether or not the survival or dis-
tant metastasis-free probability (DMFP) differences
between the possible subtypes were significant. (See Fig-
ure 7.)
Overall level of significance
Throughout this analysis an α = 0.05 level of significance
was used. The level of significance for the entire procedure
may not be α = 0.05, however. At four distinct junctures
in the analysis, α played a role but was not adjusted to
account for multiple hypothesis testing. First, α = 0.05 was
used to determine which of the 169 seed genes were can-
didate genes. Second, α = 0.05 was used to determine
which gene pairs induced sets of groups that were vali-
dated in the training dataset. Third, α = 0.05 was used to
determine which of the sets of groups that were validated
in the training dataset were also validated in the testing
datasets. Finally, α = 0.05 was used to determine which of
sets of groups that were validated in all datasets were dif-
ferent clinically.
In the first three steps of the analysis many Type I errors
could be generated, but they are very unlikely to pass
through the latter two steps. To estimate the rate of false
positives, a cursory analysis was carried out (data not
shown). The data in each row of all the datasets were per-
muted independently. Then the analysis described above
to was conducted for a portion of the sets of three groups
that were generated. Of the 100 sets examined, thirty-two
were validated in the training dataset, but none were vali-
dated in all of the datasets. This suggest that while early
steps in the procedure are prone to Type I errors, the later
steps reduce the number of Type I errors to a level below
α = 0.05.
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